Immune thrombocytopenia (ITP) trials in Norway

In Norway 8 Also abroad 118

8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Where
Graalum
Age
18 years and over
People
60 worldwide
Run by
Sanofi
See details and how to joinNCT07007962 · EU 2025-522070-36-00
Phase 1/2Taking people
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Where
Bergen, Fredrikstad, Trondheim
Age
18 years to 64 years
People
68 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06721013 · EU 2024-518502-40-00
Phase 3Taking people
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Where
Bergen, Graalum, Loerenskog
Age
18 years and over
People
171 worldwide
Run by
Takeda
See details and how to joinNCT06722235 · EU 2024-514401-54-00
Phase 1Taking people
Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
Where
Graalum, Kristiansand S, Stavanger
Age
18 years and over
People
78 worldwide
Run by
Chugai Pharmaceutical Co. Ltd.
See details and how to join2024-511346-39-00
Phase 3Taking people
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Where
Bergen, Graalum, Loerenskog
Age
18 years and over
People
150 worldwide
Run by
Takeda
See details and how to joinNCT06948318 · EU 2025-521692-31-00
Phase 3Taking people
Comprehensive Evaluation of Two Second-Line Therapeutic Approaches for Immune Thrombocytopenia (ITP) – a Pragmatic Randomized Controlled Trial - Holistic Study
Where
Bergen, Bodo, Fredrikstad, Haugesund, Kristiansand S, Levanger, Loerenskog, Oslo, Stavanger, Tonsberg, Tromsoe, Trondheim
Age
18 years and over
People
220
Run by
Ostfold Hospital Trust
See details and how to join2023-505573-32-00
Phase 1Taking people
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Where
Graalum, Kristiansand S, Stavanger
Age
18 years to 85 years
People
144 worldwide
Run by
Chugai Pharmaceutical
See details and how to joinNCT06371417 · EU 2023-507692-21-00
Phase 1Enrolling by invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
Where
Kristiansand, Stavanger
Age
18 years to 85 years
People
144 worldwide
Run by
Chugai Pharmaceutical
See details and how to joinNCT06723106